Ronny Gal - The New York office of the U.S. Attorney's Office for the District of New York announced today that it filed a civil injunctive action and obtained an emergency court order to halt the litigation.  The SEC's complaint, filed in federal court in New York, alleges that AbbVie Inc. and its CEO, Christine Severino, violated the antifraud provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder. The complaint alleges that AbbVie violated the antifraud provisions of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. Without admitting or denying the allegations in the complaint, AbbVie and its CEO have agreed to the entry of a final judgment that permanently enjoins them from violating Section 10(b) of the Exchange Act. The settlement is subject to court approval. The SEC's complaint charges AbbVie and its CEO with violating Section 10(b) and Rule 10b-5 thereunder, and seeks disgorgement of ill-gotten gains plus interest, penalties, and injunctive relief. The settlement is subject to court approval. Without admitting or denying the allegations in the SEC's complaint, AbbVie has agreed to the entry of a final judgment permanently enjoining it from future violations of Section 10(b) of the Exchange Rules and Rule 10b-5 thereunder. In a parallel action, the U.S. Attorney's Office for New York today announced criminal charges against Christine Severino. The settlement is subject to court approval.  The SEC's investigation was conducted by Ronny Gal and supervised by Kelly L. Gibson. The litigation will be led by Christine Severino. The SEC appreciates the assistance of the U.S. Attorney's Office, the Federal Bureau of Investigation, and the Financial Industry Regulatory Authority.